Drug Profile
Bevacizumab biosimilar - Mycenax Biotech
Alternative Names: AiNEXLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Mycenax Biotech
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Colorectal-cancer(Metastatic disease) in Taiwan (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Glioblastoma in Taiwan (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Taiwan (Parenteral)